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Abstract
Signaling lymphocyte activation molecules (SLAMs) play an integral role in
immune regulation. Polymorphisms in the SLAM family receptors are implicated
in human and mouse model of lupus disease. The lupus-associated, somatically
mutated, and class-switched pathogenic autoantibodies are generated in
spontaneously developed germinal centers (GCs) in secondary lymphoid organs.
The role and mechanism of B cell-intrinsic expression of polymorphic SLAM
receptors that affect B cell tolerance at the GC checkpoint are not clear. In
this study, we generated several bacterial artificial chromosome-transgenic mice
that overexpress C57BL/6 (B6) alleles of different SLAM family genes on an
autoimmune-prone B6.Sle1b background. B6.Sle1b mice overexpressing B6-
derived Ly108 and CD84 exhibit a significant reduction in the spontaneously
developed GC response and autoantibody production compared with B6.Sle1b
mice. These data suggest a prominent role for Sle1b-derived Ly108 and CD84
in altering the GC ...
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The Journal of Immunology
B Cell–Intrinsic CD84 and Ly108 Maintain Germinal
Center B Cell Tolerance
Eric B. Wong,* Chetna Soni,* Alice Y. Chan,†,1 Phillip P. Domeier,* Shwetank,*
Thomas Abraham,‡ Nisha Limaye,†,2 Tahsin N. Khan,*,3 Melinda J. Elias,*
Sathi Babu Chodisetti,* Edward K. Wakeland,† and Ziaur S. M. Rahman*
Signaling lymphocyte activation molecules (SLAMs) play an integral role in immune regulation. Polymorphisms in the SLAM
family receptors are implicated in human and mouse model of lupus disease. The lupus-associated, somatically mutated, and class-
switched pathogenic autoantibodies are generated in spontaneously developed germinal centers (GCs) in secondary lymphoid
organs. The role and mechanism of B cell–intrinsic expression of polymorphic SLAM receptors that affect B cell tolerance at the
GC checkpoint are not clear. In this study, we generated several bacterial artificial chromosome–transgenic mice that overexpress
C57BL/6 (B6) alleles of different SLAM family genes on an autoimmune-prone B6.Sle1b background. B6.Sle1b mice overexpress-
ing B6-derived Ly108 and CD84 exhibit a significant reduction in the spontaneously developed GC response and autoantibody
production compared with B6.Sle1b mice. These data suggest a prominent role for Sle1b-derived Ly108 and CD84 in altering the
GC checkpoint. We further confirm that expression of lupus-associated CD84 and Ly108 specifically on GC B cells in B6.Sle1b
mice is sufficient to break B cell tolerance, leading to an increase in autoantibody production. In addition, we observe that
B6.Sle1b B cells have reduced BCR signaling and a lower frequency of B cell–T cell conjugates; the reverse is seen in B6.Sle1b
mice overexpressing B6 alleles of CD84 and Ly108. Finally, we find a significant decrease in apoptotic GC B cells in B6.Sle1b mice
compared with B6 controls. Our study establishes a central role for GC B cell–specific CD84 and Ly108 expression in maintaining
B cell tolerance in GCs and in preventing autoimmunity. The Journal of Immunology, 2015, 194: 4130–4143.
T
he signaling lymphocyte activation molecule (SLAM)
family receptors play critical roles in immune regulation
and are required for an effective humoral response (1, 2).
The Sle1b sublocus derived from the lupus-prone NZM2410/NZW
strain harbors the SLAM family (Slamf) genes (3). Previous stud-
ies suggested that Slamf genes are major players in mediating
the loss of tolerance to nuclear Ags and in the development of
autoimmunity in C57BL/6 (B6).Sle1b mice (3). Polymorphisms in
the Ly108/Slamf6 gene are implicated in the loss of early B cell–
mediated (4), as well as peripheral T cell–mediated, tolerance (5).
Several independent studies suggested the contribution of three
other SLAMF genes, Slamf1 (SLAM/CD150), Slamf2 (CD48), and
Slamf3 (Ly9), in autoimmunity (6–8). However, the role of B cell–
intrinsic expression of different isoforms of Ly108 or other SLAM
receptors in the regulation of B cell tolerance at the germinal center
(GC) checkpoint remains unclear. Elucidation of the mechanism
by which SLAM receptors regulate GCs is important, because GCs
develop spontaneously in autoimmune mice and humans and gen-
erate somatically mutated and class-switched pathogenic auto-
antibodies (9–11).
Because Slamf genes are genetically linked, it has been diffi-
cult to determine the potential role of polymorphisms in a specific
family member in autoimmunity using knockout mice generated
in an autoimmune 129 background and subsequently backcrossed
to B6 mice (6–8, 12, 13). It is also unclear whether non-Slamf
genes located in Sle1b contribute to a break in B cell tolerance
given the presence of nonsynonymous mutations in these genes
in autoimmune B6.Sle1b mice (3). To definitively determine the
role of particular Slamf and/or non-Slamf genes within the Sle1b
sublocus in the development of autoimmunity and to study the
mechanisms by which these genes affect B cell tolerance at the
GC checkpoint, we used a bacterial artificial chromosome (BAC)-
transgenic rescue approach. We generated six BAC-transgenic mouse
lines expressing B6 alleles of the different genes spanning the
entire Sle1b sublocus and then bred them onto B6.Sle1b mice. The
B6.Sle1b BAC-transgenic mouse line containing B6 alleles of
Ly108 and CD84 (designated Sle1b-BAC90) showed a significant
reduction in anti-nuclear Ab (ANA) titers and positivity (pene-
trance) and a decreased spontaneously developed GC (Spt-GC) re-
sponse, indicating a critical role for Ly108 and CD84 in maintaining
GC B cell tolerance.
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Both CD84 and Ly108 are essential in maintaining tolerance be-
cause B6.Sle1b BAC-transgenic mice expressing the B6 allele of
Ly108 alone showed only a partial restoration of tolerance to ANA.
Using a conditional deletion (Cre-LoxP) system, we showed that GC
B cell–specific expression of autoimmune-prone CD84 and Ly108
genes is sufficient for the loss of B cell tolerance. B cell function
assays revealed that polymorphisms in the CD84 and Ly108 proteins
in B6.Sle1b B cells helped B cells escape tolerance by lowering BCR
signaling, decreasing apoptosis, and attenuating B cell–T cell inter-
actions. Normalization of B6.Sle1b-derived CD84 and Ly108 by
overexpression of wild-type CD84 and Ly108 restored BCR signal-
ing and B cell–T cell interactions. Our results highlight the vital role
of GC B cell–specific Ly108 and CD84 expression and function in
the maintenance of B cell tolerance at the GC checkpoint.
Materials and Methods
Mice
Breeding pairs of B6, GC B cell Cre (C.129P2[Cg]-Ighg1tm1[IRES-cre]Cgn/J),
and OT-II–transgenic (B6.Cg-Tg [TcraTcrb]425Cbn/J) mice were origi-
nally purchased from The Jackson Laboratory, and mice were bred in-
house. Derivation of B6 mice congenic for the Sle1b sublocus (named
B6.Sle1b) was described previously (14). All animals were housed in the
specific pathogen–free animal facility at Penn State Hershey Medical
Center, and all procedures were performed in accordance with the guide-
lines approved by the Pennsylvania State University College of Medicine
Institutional Animal Care and Use Committee.
Generation of BAC-transgenic mice
BACs were identified from the B6-derived BAC library (BACPAC Re-
sources, Oakland, CA). The following BACs were used: RPCI-23 194D6
(BAC41), RPCI-23 48O11 (BAC47), RPCI-23 171K8 (BAC25), RPCI-23
145F9 (BAC40), RPCI-23–388C4 (BAC90), RPCI-23 462J8 (BAC95), and
RPCI-23 438K9 (BAC-Ly108). Bacterial cultures from these BAC clones
were grown in Luria broth with chloramphenicol (12.5 mg/ml) overnight at
37˚C. QIAGEN Midi Kit solutions, P1, P2, and P3, were used to isolate
BAC DNA (QIAGEN, Valencia, CA). The DNA was purified further by
phenol-chloroform extraction, followed by cesium chloride gradient ul-
tracentrifugation. BAC DNA was diluted to 50 ng/ml in 10 mM Tris-HCl
[pH 7.5] and 0.1 mM EDTA and injected into fertilized oocytes derived
from B6 mice. Founder lines were identified by PCR specific for the vector
ends and then bred onto the respective genetic backgrounds.
Generation of floxed BAC90 mice
The BAC (RPCI-23–388C4) used to generate floxed BAC90 mice was
purchased from BACPAC Resources. The BAC vector backbone already
contained LoxP sites that flanked the insert (B6-derived CD84 and
Ly108). No additional manipulation was made to the backbone. BAC vector
DNA amplification, purification, and injection into B6-derived fertilized
oocytes were performed as described above (“Generation of BAC-
transgenic mice”).
Flow cytometry
The following Abs were used for flow cytometric analysis of mouse
splenocytes or bone marrow (BM) cells. Pacific Blue–anti-B220 (RA3-
6B2), Alexa Fluor 700–anti-CD4 (RM4-5), PE–anti-PD-1 (29F.1A12),
PerCP–Cy5.5–anti-CD69 (H1.2F3), allophycocyanin–Cy7–anti-CD25 (PC61),
Cy5–anti-CD86 (GL1), PE-Cy7–anti-CD95 (FAS, Jo2), PE-Cy7–anti-MHC
class II (M5/114.15.2), allophycocyanin–anti-CD24 (HSA) (M1/69), biotin–
anti-Ly5.1 (BP-1) (6C3), FITC–anti-CD23 (B3B4), and PE–Cy5–streptavidin
(SA) were from purchased from BioLegend (San Diego, CA). Biotin–
anti-CXCR5 (2G8) was purchased from BD Pharmingen (San Diego, CA).
FITC–peanut agglutinin (PNA) was purchased from Vector Labs (Bur-
lingame, CA). PE–anti-IgM (eB121-15F9), allophycocyanin anti-CD93
(AA4.1), and FITC–anti-F4/80 (BM8) were purchased from eBioscience
(San Diego, CA). The following Abs were used for phosphoflow analysis
of purified mouse B cells: PE–anti-Btk (pY223)/ItK (pY180) (N35-86),
Alexa Fluor 647–anti-ERK1/2 (pT202/pY204) (20A), Pacific Blue–anti-p38
MAPK (pT180/pY182), and Alexa Fluor 488–anti-Syk (pY348) (I120-722).
Stained cells were analyzed using a BD LSR II flow cytometer (BD Bio-
sciences, Franklin Lakes, NJ). Data were acquired using FACSDiva soft-
ware (BD Biosciences, San Jose, CA) and analyzed using FlowJo software
(TreeStar, San Carlos, CA).
Immunohistology
The following Abs and reagents were used for immunohistochemical
analysis of mouse spleen sections: PE–anti-CD4 (GK1.5), FITC-GL7,
and allophycocyanin–anti-IgD (all from BD Biosciences). Spleen cryostat
sections (5–6 mm) were prepared as previously described (15). Immuno-
histochemistry was performed as described (15), and stained sections were
analyzed with a Leica DM4000 fluorescence microscope and Leica soft-
ware (Leica Microsystems, Buffalo Grove, IL). The color intensity of the
images was enhanced slightly using Adobe Photoshop CS4 (Adobe Sys-
tems, San Jose, CA) for better visualization; it was carried out consistently
among all sections while maintaining the integrity of the data.
ELISPOT assays
ELISPOT assays were performed as previously described (16). Briefly,
splenocytes in 10% RPMI 1640 were plated at a concentration of 1 3 105
cells/well onto anti-IgM–coated or anti-IgG–coated (Invitrogen, Grand
Island, NY) multiscreen 96-well filtration plates or at a concentration of
1 3 106 cells/well on dsDNA-, histone-, or nucleosome-coated multi-
screen 96-well filtration plates (Millipore, Bedford, MA). Serially diluted
(1:2) cells were incubated for 6 h at 37˚C. IgM-producing Ab-forming
cells (AFCs) were detected using biotinylated anti-mouse IgM (Jackson
ImmunoResearch, West Grove, PA) and SA–alkaline phosphatase (Vector
Laboratories, Burlingame, CA). IgG-producing AFCs were detected using
alkaline phosphatase–conjugated anti-mouse IgG (Molecular Probes,
Grand Island, NY). dsDNA-, histone-, and nucleosome-specific AFCs were
detected by biotinylated anti-k Ab (Invitrogen, Grand Island, NY) and SA–
alkaline phosphatase (Vector Laboratories) or alkaline phosphatase–con-
jugated anti-mouse IgG (Molecular Probes, Grand Island, NY). Plates were
developed using the Vector Blue AP Substrate Kit III (Vector Laborato-
ries). ELISPOTs were enumerated and analyzed using a computerized
imaging/analysis system (Cellular Technology, Shaker Heights, OH).
Serology: Ig and autoantibody titers
ELISA plates were coated with anti-IgM or anti-IgG capture Abs (Invi-
trogen) and detected using biotinylated anti-mouse IgM (Jackson Immuno-
Research) or alkaline phosphatase–conjugated anti-mouse IgG (Molecular
Probes). Total IgG autoantibody titers were measured in ELISA plates coated
with dsDNA, histone, nucleosome, Smith/ribonucleoprotein (Sm/RNP), or
cardiolipin and detected with biotinylated anti-k Ab (Invitrogen). IgG subtype-
specific autoantibody titers were detected by biotinylated IgG1, biotinylated
IgG2b, and alkaline phosphatase–IgG2c Abs (Southern Biotech, Birming-
ham, AL). Biotinylated Abs were detected by SA–alkaline phosphatase
(Vector Laboratories). The plates were developed using PNPP (disodium salt;
Thermo Fisher Scientific, Rockford, IL) substrates for alkaline phosphatase.
In vitro B cell–proliferation assay
Naive B cells were purified from the indicated mice with mouse anti-CD43
(Ly-48) MicroBeads. Purified B cells were stained with 3 mM CFSE
(Sigma-Aldrich, St. Louis, MO) in PBS with 5% FBS for 15 min at room
temperature. Stained B cells were cultured with 25 mg/ml soluble anti-IgM
(Jackson ImmunoResearch) and 20 mg/ml soluble anti-CD40 Ab (Bio-
Legend). After 72 h of stimulation, cells were acquired using a BD LSR II
flow cytometer.
Ex vivo apoptosis–detection assay
Total splenocytes from 3–4-mo-old female mice of the indicated strains
were stained in vitro with SR FLICA Poly Caspase detection reagent (AbD
Serotec, Kidlington, U.K.) for 30 min at 37˚C in a water bath, followed by
staining with the indicated GC B cell markers. Cells were acquired im-
mediately after staining on the BD LSR II cytometer. DAPI+ dead cells and
doublets were gated out during the analysis.
Cell cycle analysis
B cells were cultured with anti-IgM (25 mg/ml) and anti-CD40 (20 mg/ml)
for the indicated times, harvested, washed with chilled PBS, and fixed with
chilled 70% ethanol overnight at 220˚C. Subsequently, cells were centri-
fuged at 1000 3 g for 10 min at 4˚C, washed with PBS, and stained with
propidium iodide (PI) staining solution, containing 50 mg/ml PI, 50 mg/ml
RNase A (Roche Applied Sciences, Indianapolis, IN), and 100 mM EDTA
in PBS, for 1–2 h at 42˚C. Cells were analyzed by flow cytometry.
Calcium flux assay
Naive B cells were purified from each group of mice with mouse anti-CD43
(Ly-48) MicroBeads. Purified B cells were stained with Fura Red (10 mM)
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and Fluo-3 (5 mM) (Invitrogen) in dyeless RPMI 1640 (Mediatech) for
45 min at 37˚C. A baseline calcium reading was acquired for 1 min before
the addition of 5 or 10 mg/ml anti-IgM (Jackson ImmunoResearch), fol-
lowed immediately by a 3-min acquisition through the BD LSR II flow
cytometer.
B cell–T cell in vitro conjugate assay
Naive B cells from each indicated group of mice were purified with mouse
anti-CD43 (Ly-48) MicroBeads, stained with 5 mM CellTrace Violet
(Invitrogen), and activated with 25 mg/ml soluble anti-IgM and 1 mg/ml
LPS for 24 h at 37˚C. Naive T cells from OT-II–transgenic mice were
purified with a pan-T isolation kit (Miltenyi Biotec), stained with 3 mM
CFSE, and activated with 10 mg/ml anti-CD3 and 2 mg/ml anti-CD28 for
24 h at 37˚C. A total of 10 mg/ml OVA peptide (InvivoGen, San Diego,
CA) was added to the B cells 3 h prior to the start of the assay. A total of
1 3 106 B cells and 1 3 106 T cells were placed together for the stipulated
times, fixed with 4% paraformaldehyde, and acquired using a BD LSR II.
Phosphoflow analysis
Splenocytes isolated from each indicated mouse group were activated with
25 mg/ml anti-IgM for the indicated times at 37˚C. Following activation,
cells were fixed with Lyse/Fix (BD) for 10 min at 37˚C. Following washes,
cells were permeabilized with Perm/Wash Buffer (BD) for 30 min at room
temperature. Following two washes with Perm/Wash Buffer, cells were
stained for anti-B220 and phosphoflow Abs (BD) described above for 1 h.
Samples were acquired using a BD LSR II flow cytometer.
Assessment of GC sizes
Immunohistochemistry was performed using the Abs listed in the “Immu-
nohistology” section, and stained sections were analyzed with a Leica
DM4000 fluorescence microscope and Leica software (Leica Micro-
systems). Ten randomly selected GCs/mouse from the indicated mouse
groups (five mice from each group) were assessed for total area (mm2)
using Leica Microsystems software.
In vitro B cell–functional assays
B cells were purified from naive B6, B6.Sle1b, or Sle1b-BAC90 mice with
mouse anti-CD43 (Ly-48) MicroBeads, stimulated with 25 mg/ml anti-
IgM, 10 mg/ml anti-CD40, and/or 5 mg/ml anti-Ly108 (13G3-19D) (eBio-
science) or 2 mg/ml recombinant CD84 agonist (R&D Systems) for 24 h, and
acquired using a BD LSR II flow cytometer.
DNA/RNA preparation and real-time RT-PCR
Total DNA was isolated with a DNeasy Blood and Tissue kit (QIAGEN,
Hilden, Germany), following the manufacturer’s guidelines, from the tails of
the indicated mice. Gene expression was quantified using TaqMan Master
Mix and the StepOnePlus Real-Time PCR system (Applied Biosystems,
Grand Island, NY). Primers for CD84 and Ly108 copy number assay were
purchased from Life Technologies. Amplification conditions for all primer
sets were 1 cycle at 95˚C for 10 min, followed by 40 cycles at 95˚C for 15 s
and 60˚C for 1 min. Mouse Tert was used as the reference gene.
Total RNA was isolated from purified B cells and T cells or from GC
B cells and follicular helper T cells (Tfh cells) sorted with a FACSAria
Sorter using the RNeasy Mini Kit (QIAGEN), following the manufacturer’s
guidelines. RNAwas reverse transcribed using the High-Capacity Reverse
Transcription kit (Applied Biosystems). Gene expression was quantified
using TaqMan PCR Master Mix kit or Power SYBR Green PCR Master
Mix Kit using the StepOnePlus Real-Time PCR System (all from Applied
Biosystems). Primers for the SLAM genes were purchased from Life
Technologies, and Ly108 isoform primers were designed using Primer3
software and synthesized by IDT Technologies (Coralville, Iowa). The
following primer sequences were used: Ly108.1: forward 59-CTCGT-
CCAATGCAGGAAATG-39 and reverse 59-AGATGTGTTCTCCCTGGA-
TTTC-39; Ly108.2: forward 59-CTCGTCCAATGCAGGAAATG-39 and
reverse 59-AGGAGTTATAGTTGATTAAG-39; and Ly108-H1: forward
59-AGCACAGATGGCCCAGG-39, reverse 59-AGGAGTTATAGTTGAT-
TAAAG-39. Amplification conditions for all primer sets were 1 cycle at
95˚C for 10 min, followed by 40 cycles at 95˚C for 15 s and 60˚C for
1 min. GAPDH was used as the reference gene for sample normalization.
Extracellular flux analysis
Oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) were measured in a XF96 extracellular flux analyzer using a kit,
as per manufacturer’s instructions (Seahorse Bioscience, Boston, MA).
Briefly, B cells from B6, B6.Sle1b, and Sle1b-BAC90 mice were purified
by negative selection using CD43 MicroBeads by MACS purification
(Miltenyi Biotec). Purified B cells were stimulated with 25 mg/ml anti-IgM
and 20 mg/ml anti-CD40 for 18 h in RPMI 1640 + 10% FCS. Thereafter,
6 3 105 activated B cells were plated in XF media (Seahorse Bioscience)
with 25 mM glucose onto a Cell-Tak (BD Biosciences)-coated XF96 plate.
Oligomycin (1 mM), carbonyl cyanide 4- (trifluoromethoxy) phenyl hydra-
zone (2 mM), rotenone (1 mM), and antimycin (1 mM) were added sequen-
tially, and measurements of extracellular flux were recorded. Glycolysis was
calculated from ECAR values at the basal respiration phase, and glycolytic
capacity was calculated from ECAR values after the inhibition of ATP
synthase by the addition of oligomycin, when cells resort to meeting their
energy demands using their maximum glycolytic capacity. OCR and ECAR
data were analyzed using Wave software and plotted using GraphPad Prism
v6.0 (La Jolla, CA).
Two-dimensional live cell microscopy, image acquisition, and
cell-tracking analysis
For the live cell-tracking measurements, the confocal technique (Leica AOBS
SP8 laser scanning confocal microscope; Leica Microsystems, Heidelberg,
Germany) was used along with a heated live cell stage equipped with a hu-
midified 5% CO2 perfusion system (TOKAI HIT). The live cell data mode
(xyt) in the image-acquisition software (Leica Confocal Software LAF) was
used for the two-dimensional (2D) imaging of live cells. Activated B cells
loaded with OVA peptide and labeled with CellTrace (Invitrogen) were mixed
with activated CFSE-labeled OT-II T cells in 0.5 mg/ml collagen solution, pH
7 (TelCol, type 1 acid-soluble collagen solution from Advanced BioMatrix,
San Diego, CA). 2D live cell images of B and T cell contacts were acquired
sequentially using the 633/1.2 high numerical aperture apochromatic water-
immersion objective every 30 s for 1 h. The laser lines for excitation included
UV diode, 80 MHz white light laser (Leica AOBS SP8 module), and the
emission signals were collected sequentially using AOBS tunable filters to
eliminate cross-talk and cross-excitation. All of the fluorescent images, as
a function of time, were collected using highly sensitive HyD detectors (with
time gated option). The images (8 bit) were line-averaged to minimize the
random noise, and a pixel format of 5123 512 was selected. For each sample,
2D time-series images were compiled, and cell tracking was performed using
Imaris and Imaris XT (Bitplane, Switzerland) functions, based on the Matlab
program. The data were compiled in Microsoft Excel (Microsoft, Redmond,
WA) sheets, and final plots, slope measurements, and statistical analysis were
performed using GraphPad Prism v6 or Origin Lab v9.1.
Statistical analysis
Unpaired, nonparametric, Mann–Whitney, and Student t tests were used for
comparing two groups, and one-way ANOVA followed by Tukey’s multiple
comparison test was used for comparing more than two groups. GraphPad
Prism 6 analytical tool (La Jolla, CA) was used for every analysis. Wherever
indicated, NS = nonsignificant, *p # 0.05, **p # 0.01, ***p # 0.001, and
****p # 0.0001. Error bars reflect mean values, unless otherwise noted.
Results
A major role for SLAM family receptors CD84 and Ly108 in
maintaining tolerance
SLAM family genes, located in the telomeric end of chromosome 1 in
autoimmune mice (i.e., NZM2410/NZW-derived Sle1b interval) and
human systemic lupus erythematosus patients, are implicated in altering
B cell tolerance (3, 16–18). To definitively determine the contribution
of particular Slamf genes within the Sle1b sublocus in autoimmunity,
a panel of B6-derived BACs spanning the entire Sle1b interval was
used to generate a series of transgenic mouse lines (Fig. 1A).
Multiple founder lines carrying different copy numbers were gen-
erated for each BAC (Fig. 1A). Of the six BAC-transgenic mouse lines
generated, only the BAC transgene carrying B6 alleles of CD84 and
Ly108 (referred to as BAC90) was able to significantly suppress both
ANA positivity/penetrance (Fig. 1B) and titers (Fig. 1C) when bred
to B6.Sle1b mice (referred to as Sle1b-BAC90). The BAC transgene
carrying 2B4 (Slamf4), Ly9 (Slamf3), and Cs1 (Slamf7) (referred to
as BAC25) also had lower ANA titers (Fig. 1C), but 70% of B6.Sle1b
mice expressing the BAC25 transgene (designated Sle1b-BAC25)
remained positive for ANA (Fig. 1B). When we analyzed ANA titers
in B6.Sle1b mice expressing each founder line for a given BAC-
transgenic strain, we did not find a significant difference among the
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individual founder lines, with the exception of BAC25 and BAC90
(Supplemental Fig. 1). Of the three BAC90-transgenic founder lines
generated, two (BAC90-4389 and BAC90-4390) had significantly
lower ANA titers than the third (BAC90-4270). A significant dif-
ference in ANA titers was observed between BAC90-4270 and
BAC90-4389 lines (Supplemental Fig. 1). We also observed a dif-
ference between the two BAC25 lines (Supplemental Fig. 1).
To determine whether Ly108 alone was able to mediate the
suppression of ANA production in Sle1b-BAC90 mice, a BAC-
transgenic mouse carrying only the B6 allele of Ly108 was
generated and bred onto the B6.Sle1b background (referred to
as Sle1b-BAC-Ly108). Sle1b-BAC-Ly108 mice displayed a re-
duction in serum ANA penetrance and titers (Supplemental
Fig. 2), but not to the extent that was observed in aged Sle1b-
BAC90 mice that carry both CD84 and Ly108 (Fig. 1B, 1C).
These data indicate that allelic variations in both CD84 and
Ly108 were required to break tolerance to nuclear self-Ags in
B6.Sle1b mice.
Restoration of B cell tolerance at the GC checkpoint by
overexpression of B6-derived CD84 and Ly108
Sle1b alters peripheral B cell tolerance at the GC checkpoint,
leading to elevated Spt-GC and Tfh cell responses (16). We
asked whether introduction of the B6 wild-type alleles of CD84
and Ly108 into B6.Sle1b mice could restore tolerance by regu-
lating the GC checkpoint in B6.Sle1b mice. We first evaluated
the surface expression and found that CD84 and Ly108 levels
were higher in B cells from B6.Sle1b and Sle1b-BAC90 mice
compared with B6 mice at 2 mo of age (Supplemental Fig. 3A).
However, B6.Sle1b B cells exhibited a significant reduction in
both CD84 and Ly108 surface expression by 8 mo compared
with B6 and Sle1b-BAC90 B cells (Supplemental Fig. 3B). A
similar temporally biphasic expression profile for CD84 and
Ly108 was observed when GC B cells were analyzed at 2 and
8 mo of age (data not shown). CD84 expression on CD4+ T cells
remained similar among the three strains, but Ly9 and Ly108
levels on CD4+ T cells were higher in B6.Sle1b and Sle1b-
BAC90 mice than in B6 mice at both 2 and 8 mo of age (data not
shown). We observed no difference in SLAM adaptor (SAP)
molecule transcript levels in B cells and T cells from these mice
(data not shown).
Immunohistological analysis of spleens revealed smaller and
less frequent Spt-GCs in B6 and Sle1b-BAC90 mice compared with
B6.Sle1b mice (Fig. 2A, 2B). This decrease in Spt-GCs was con-
firmed by flow cytometric analysis of splenocytes, which showed
a significant reduction in the percentage of B220+FashiPNAhi Spt-GC
FIGURE 1. Suppression of ANA production in B6.Sle1bmice overexpressing B6-derived CD84 and Ly108. (A) Schematic diagram of the six B6-derived
BACs spanning the Sle1b interval. Each BAC harbors B6 alleles that genetically complement the indicated region in the Sle1b interval. Founders had
variable copy numbers (low copy [1, 2], medium copy [3, 4], and high copy [.10]). (B) Six BACs carrying the B6 alleles of the Sle1b genes were crossed to
B6.Sle1b mice, and two or three founder lines for each BAC were analyzed for IgG-specific ANA positivity at 7 mo of age. Statistical analysis was
performed using logistic regression (SAS version 9.1). (C) IgG ANA titers were assessed in 7-mo-old BAC-transgenic mice. Dotted line represents the value
that is four SD above the mean titer from B6 mice. ANA titers in Sle1b-BAC25 and Sle1b-BAC90 mice (open circles) were significantly higher than in
B6.Sle1b mice (p , 0.01 and p , 0.001, respectively). *p , 0.05, **p , 0.01, ***p , 0.001.
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B cells in 6–8-mo-old Sle1b-BAC90 female mice compared with
age-matched B6.Sle1b females (Fig. 2C). There was a strong inverse
correlation between the percentage of GC B cells and the levels of
Ly108 and CD84 expression on GC B cells (data not shown). Next,
we asked whether the decrease in Spt-GCs in Sle1b-BAC90 mice
resulted in a decline in the Tfh cell response. B6 and Sle1b-BAC90
mice had similar percentages of CD4+CXCR5hiPD-1hi Tfh cells,
CD4+CD44hiCD62Llo short-lived effector/effector memory T cells,
and CD4+CD44hiCD62Lhi central memory T cells, all of which were
significantly lower than in B6.Sle1b mice (Fig. 2D, 2E). These data
suggest the cooperative function of CD84 and Ly108 in maintaining
GC B cell tolerance.
Wild-type CD84 and Ly108 prevent development of
ANA-specific AFCs and serum autoantibody titers
Next, we asked whether the reduction in Spt-GC responses in Sle1b-
BAC90 mice resulted in decreased ANA-specific AFCs and Ab
titers. B6 and Sle1b-BAC90 mice had significantly lower numbers
of dsDNA-, histone-, and nucleosome-specific AFCs in the spleen
(Fig. 3A–C), as well as total serum IgM and IgG titers (Fig. 3D,
3E), than did B6.Sle1b mice. Sle1b-BAC90 mice also exhibited
significantly reduced levels of IgG2c-specific Abs against dsDNA,
histone, nucleosome (Fig. 3F–H), Sm/RNP, and cardiolipin (Fig. 3J,
3K) as well as IgG2b-specific anti-nucleosome Abs (Fig. 3I) com-
pared with B6.Sle1b mice. The reduced autoantibody levels in
Sle1b-BAC90 mice strongly correlated with the lower percentage of
Spt-GC B cells (data not shown).
The cardinal function of GCs is the generation of long-lived
AFCs, which primarily reside in BM (19). We asked whether el-
evated Spt-GC and Tfh cell responses in B6.Sle1b mice resulted in
more ANA-specific, long-lived BM AFCs and whether the ele-
vated ANA-specific BM AFC response in B6.Sle1b mice could be
reversed by the introduction of B6 alleles of CD84 and Ly108 in
Sle1b-BAC90 mice. Although there were significantly higher num-
bers of ANA-specific AFCs in the BM of B6.Sle1b mice, their
numbers were markedly reduced in Sle1b-BAC90 mice (Fig. 3L–N).
FIGURE 2. Restoration of B cell tolerance in
GCs in Sle1b-BAC90 mice expressing wild-type
CD84 and Ly108. (A) Representative immuno-
histological images of spleen sections from
three to five mice/group, stained with GC B cell
marker GL7 (green), CD4 T cell marker (red),
and follicular B cell marker IgD (blue). (B)
Scatterplot of the range of GC sizes from each
mouse strain. (C) Flow cytometric analysis of
the percentage of B220+FashiPNAhi GC B cells.
Each symbol represents an individual mouse. (D
and E) Percentage of Tfh cells (CD4+CXCR5hi
PD-1hi), short-lived effector/effector memory
T cells (CD4+CD44hiCD62Llo), and central
memory T cells (CD4+CD44hiCD62Lhi). Each
symbol represents an individual mouse. *p ,
0.05, **p , 0.01, ***p , 0.001.
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The reduction in Spt-GC, Tfh cell, and ANA responses in Sle1b-
BAC90 mice was not the result of global suppression of the ability of
B cells to mount an immune response, because no differences were
observed in the foreign Ag–specific GC, Tfh cell, and Ab responses
among B6, B6.Sle1b, and Sle1b-BAC90 mice immunized with
SRBCs (data not shown).
FIGURE 3. Reduction in ANA-specific AFCs and Ab titers in Sle1b-BAC90 mice. ELISPOT analysis of dsDNA-specific (A), histone-specific (B), and
nucleosome-specific (C) splenic AFCs in 6–8-mo-old B6, B6.Sle1b, and Sle1b-BAC90 mice. Total IgM (D) and IgG (E) serum titers at 6–8 mo of age in
each group of mice. (F–K) ELISA analysis of IgG2c-specific Abs against dsDNA, histone, nucleosome, Sm/RNP, and cardiolipin, as well as IgG2b-specific
Abs against nucleosome, at 6–8 mo of age. (L–N) ELISPOT analysis of dsDNA-, histone-, and nucleosome-specific long-lived BM AFCs in 6–8-mo-old
mice of the indicated genotypes. Each symbol represents an individual mouse. *p , 0.05, **p , 0.01, ***p , 0.001.
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Overexpression of B6-derived CD84 and Ly108 on GC B cells
is sufficient to restore tolerance in B6.Sle1b mice
To determine whether the overexpression of B6 alleles of CD84
and Ly108 within GC B cells could restore tolerance, we generated
Sle1b-BAC90fl/fl mice and crossed them with GC B cell–specific
Cg-Ighg1-Cre mice (20, 21). Quantitative PCR analysis of gene
copy number and flow cytometric analysis of surface expression
confirmed significantly reduced expression levels of the Ly108
and CD84 genes, specifically in GC B cells (Fig. 4A–D) and not in
non-GC naive B cells (data not shown), confirming GC B cell–
specific deletion of the BAC90 transgene containing B6-CD84 and
Ly108 genes in Sle1b-BAC90fl/fl-Cre mice.
Flow cytometric analysis of 4–5-mo-old Sle1b-BAC90fl/fl-Cre
mice showed increased percentages of GC B cells, Tfh cells, and
short-lived effector T cells, as well as increased CD86 expression
on B cells, compared with B6 and Sle1b-BAC90fl/fl (Cre2/2)
controls (Fig. 4E–H). These elevated responses in Sle1b-BAC90fl/fl-
Cre mice were similar to the increased responses seen in B6.Sle1b
mice (Fig. 4E–H). Immunofluorescent staining of spleen sections
with GL7, anti-IgD, and anti-CD4 confirmed the flow cytometry
data, showing increased numbers and sizes of IgD2GL7+ Spt-GCs
in B6.Sle1b and Sle1b-BAC90fl/fl-Cre mice compared with B6 and
Sle1b-BAC90fl/fl controls (Fig. 4I, 4J).
This increase in Spt-GC responses in Sle1b-BAC90fl/fl-Cre mice
resulted in elevated numbers of IgM-, IgG-, dsDNA-, histone-, and
nucleosome-specific AFCs in the spleen (Fig. 5A–E), as well as
serum IgG2c titers specific for dsDNA, histone, nucleosome,
Sm/RNP, and cardiolipin (Fig. 5F–J). Cre-mediated excision of
transgenically expressed wild-type Ly108 and CD84 from GC
B cells in Sle1b-BAC90fl/fl-Cre mice resulted in elevated numbers
of IgM-, IgG-, dsDNA-, histone-, and nucleosome-specific long-
lived AFCs in the BM (Fig. 5K–O), confirming that GC B cell–
specific B6 wild-type CD84 and Ly108 expression was sufficient
for the restoration of tolerance in B6.Sle1b mice.
Wild-type CD84 and Ly108 expression normalizes BCR
signaling, proliferation, and apoptotic capacity of B cells in
B6.Sle1b mice
Next, we determined whether elevated Spt-GC responses in
B6.Sle1b mice compared with B6 controls correlated with in-
creased proliferation of B cells that can potentially drive the au-
toimmune response. In vitro stimulation of B cells with anti-IgM
and anti-CD40 unexpectedly resulted in a reduced number of
proliferating B cells at 72 h in B6.Sle1b mice compared with B6
controls (Fig. 6A). Moreover, a significantly higher percentage of
B cells remained in the G0/G1 phase in B6.Sle1b mice, resulting in
a lower fraction of cells in the S phase compared with B6 controls
(Fig. 6B). This reduced proliferation in B6.Sle1b mice was cor-
rected in Sle1b-BAC90 mice overexpressing B6-CD84 and Ly108
(Fig. 6A, 6B). In line with the lower proliferation rate, stimulation
with anti-IgM caused a lower Ca2+ flux in B6.Sle1b B cells than in
B6 B cells (Fig. 6C). Notably, Sle1b-BAC90 mice exhibited a Ca2+
flux that was similar to B6 mice (Fig. 6C), highlighting a potential
cross-talk between BCR and SLAM signaling.
Next, to determine whether the decrease in proliferative capacity
of B6.Sle1b B cells resulted in increased apoptosis of B6.Sle1b
B cells, we evaluated B cell survival upon stimulation. In vitro
stimulation of B cells with anti-IgM and anti-CD40 resulted in
a lower percentage of apoptotic B6.Sle1b B cells compared with
B6 and Sle1b-BAC90 B cells (Fig. 6D). We also determined the
percentage of B cells undergoing apoptosis in GCs by measuring
the caspase activity in DAPI2B220+FashiPNAhi GC B cells. We
found a significant decrease in B220+PNAhiFashiCaspase+ apo-
ptotic GC B cells in B6.Sle1b mice compared with B6 controls
(Fig. 6E). Overall, the percentage of apoptotic GC B cells in Sle1b-
BAC90 mice was higher than in B6.Sle1b mice, but the difference
was not statistically significant (Fig. 6E). We observed no significant
difference in the percentage of apoptotic GC B cells between B6 and
Sle1b-BAC90 mice. Consistent with this finding, staining for apo-
ptotic TUNEL+ cells on spleen sections showed fewer apoptotic
cells/mm2 of GC area in B6.Sle1bmice than in B6 and Sle1b-BAC90
mice (Fig. 6F). Supporting the above findings, our gene-expression
analysis revealed significant upregulation of several antiapoptotic
genes in B6.Sle1b B cells compared with B6 B cells (Table I).
To determine whether there were defects in the BCR signaling
pathway in B6.Sle1b B cells, we evaluated the phosphorylation
status of BCR proximal signaling molecules (BTK and Syk) and
downstream molecules (p-38–MAPK and Erk) after BCR activation
with anti-IgM using phosphoflow analysis. Consistent with the Ca2+
flux results, B6.Sle1b B cells exhibited decreased phosphorylation
of all of these molecules (Fig. 6G–J). Introduction of the B6 alleles
of CD84 and Ly108 in Sle1b-BAC90 mice rescued this signaling
defect, further supporting the possibility of cross-talk between BCR
and SLAM signaling and indicating a role for Ly108 and CD84 in
the restoration of peripheral B cell tolerance. Our results also show
that B cells from B6.Sle1b mice were not anergic and that the re-
duced signaling activity exhibited by these B cells was not due to
primary B cell developmental defects (Supplemental Fig. 4).
Several genes encoding enzymes required for various metabolic
pathways, including those involved in cellular energy metabolism,
are modulated by the activation of B cells through BCR, CD40L,
and TLR ligands (22). Additionally, it was demonstrated that
signaling events, which lead to variations in cellular energy me-
tabolism during GC reactions, are necessary for the maintenance
and differentiation of GC B cells and plasma cells (21). Given the
aforementioned differences in BCR signaling (Fig. 6G–J), we then
asked whether B cells from B6, B6.Sle1b, and Sle1b-BAC90 mice
were metabolically different in responding to energy demands
upon activation. No significant differences were observed in the
baseline oxygen consumption among B cells from B6, B6.Sle1b,
and Sle1b-BAC90 mice following activation with anti-IgM and
anti-CD40 (Fig. 6K, 6L). ATP production after exposure to oli-
gomycin also was comparable among these three strains (Fig. 6K,
6L). In addition, B6 and B6.Sle1b B cells showed similar maxi-
mum respiration, whereas Sle1b-BAC90 B cells showed margin-
ally reduced maximal respiration, compared with B6 controls
(Fig. 6K, 6L). Notably, B6.Sle1b and Sle1b-BAC90 B cells had
significantly higher glycolysis and glycolytic capacity than did B6
B cells (Fig. 6M, 6N). These results indicate that reduced calcium
mobilization and decreased BCR signaling in B6.Sle1b B cells did
not dampen the energy metabolism in these cells.
Sle1b-expressing B cells have a lower frequency of conjugate
formation with wild-type T cells, which is reversed by the
overexpression of wild-type CD84 and Ly108
Previous studies showed that SAP expression in T cells is required
for effective B and T cell conjugation leading to optimal GC
responses during T cell–dependent antigenic stimulation or viral
infection (23, 24). The effect of B cell–intrinsic expression of
lupus-associated SLAM family receptors on conjugate formation
in the context of autoimmunity is not clear. We asked whether
polymorphic SLAM expression in B cells from B6.Sle1b mice led
to differential interaction with T cells, affecting their ability to
form B cell–T cell conjugates. We further asked whether over-
expression of B6-derived CD84 and Ly108 in B6.Sle1b B cells
could normalize such potential differences in the ability of B6.Sle1b
B cells to form conjugates with T cells.
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We used an in vitro flow cytometry–based B and T cell con-
jugation assay in which purified B cells from B6, B6.Sle1b, and
Sle1b-BAC90 mice were activated with anti-IgM and LPS and
loaded with OVA peptide to present to B6 OT-II–transgenic T cells
specific for OVA323–339. B6.Sle1b B cells formed a significantly
reduced number of conjugates over the course of 60 min compared
FIGURE 4. GC B cell–intrinsic effect of overexpression of B6 Ly108 and CD84 on restoration of tolerance. (A and B) GC B cells were sorted
(FACSAria) and analyzed for genomic expression of Ly108 and CD84, which were normalized to B6 control. (C and D) Flow cytometric analysis of Ly108
and CD84 expression levels (MFI) on GC B cells. (E) Scatter plots showing the percentages of GC B cells. (F) MFI of CD86 levels on B cells. Scatter plots
showing the percentages of Tfh cells (G) and short-lived effector/effector memory T cells (H) in 4–5-mo-old mice. (I) Representative images of spleen
sections from 4–5-mo-old mice stained with GL-7 (green), anti-CD4 (red), and anti-IgD (blue). These data represent three to five randomly picked mice/
group. (J) Scatter plot showing GC sizes for each group of mice at 4–5 mo of age. *p , 0.05, **p , 0.01, ***p , 0.001.
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with B cells from B6 mice; this was corrected when B cells were
from Sle1b-BAC90 mice (Fig. 7A).
To track B cell–T cell interactions in real time, 2D confocal
images of conjugates between activated B cells and OT-II T cells
were acquired sequentially every 30 s for 60 min (Fig. 7B, 7C).
Consistent with the flow cytometry data, the percentage of B cell–
OT-II T cell conjugates was significantly lower over time when B
cells were from B6.Sle1b mice compared with B6 or Sle1b-BAC90
FIGURE 5. GC B cell–specific excision of B6 Ly108 and CD84 in Sle1b-BAC90 mice reinstates loss of tolerance to ANA. (A–E) ELISPOTanalysis of IgM-,
IgG-, dsDNA-, histone-, and nucleosome-specific splenic AFCs in 4–5-mo-old mice. (F–J) IgG2c-specific Abs against dsDNA, histone, nucleosome, Sm/RNP,
and cardiolipin, as well as IgG2b-specific Abs against nucleosome, were measured using ELISA. (K–O) ELISPOT analysis of IgM-, IgG-, dsDNA-, histone-,
and nucleosome-specific long-lived BM AFCs at 4–5 mo. Each symbol represents an individual mouse. *p , 0.05, **p , 0.01, ***p , 0.001.
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mice (Fig. 7D, left panel). We also measured the duration of con-
tacts between OT-II T cells and B cells from each strain over
a 60-min period. We found similar B cell–T cell contact duration
time between B cells from B6 and B6.Sle1b mice. The contact
FIGURE 6. Analysis of B cell proliferation, apoptosis, signaling, and cellular metabolism. (A) In vitro proliferation of CFSE-labeled B cells stimulated
with anti-IgM and anti-CD40 (left panel). Bar graph of the percentages of proliferating B cells (right panel). (B) Cell cycle analysis of purified B cells after
anti-IgM and anti-CD40 stimulation by PI staining. (C) Calcium flux of B cells after anti-IgM stimulation. (D) Bar graph of the percentages of dead cells
after anti-IgM and anti-CD40 stimulation. (E) Contour plots show the representative gating strategy for GC B cells stained ex vivo with SR-VAD-FMK,
a Poly Caspase probe (upper panel). Bar graph shows the percentage of GC B cells positive for activated poly caspases in the indicated strains (lower
panel). Each symbol represents an individual mouse. Data are mean and SD. (F) Consecutive spleen sections were stained for IgD (blue), PNA (red), and
TUNEL (brown) (left panel). Original magnification 3100. Data are representative of five mice/group. Bar graph depicting the ratio of TUNEL+ cells and
GC size (mm2 3 103) (middle panel). Correlation between the number of TUNEL+ cells and the GC size (right panel). (G–J) Flow cytometric analysis to
evaluate the kinetics of phosphorylation of BtK, Erk, p38/MAPK, and Syk after anti-IgM stimulation of B cells. Representative plots of OCR (K) and ECAR
(M) in B6, B6.Sle1b, and Sle1b-BAC90 B cells stimulated with anti-IgM and anti-CD40 for 18 h. (L) Bar graph of average basal oxygen consumption; ATP
production through ATP synthase and the maximal electron transport capacity of activated B cells from three or four mice/group. (N) Bar graph of average
ECAR values for glycolysis and the glycolytic capacity of activated B cells from three or four mice/strain. *p # 0.05, **p # 0.01, ***p # 0.001.
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duration time was higher with B cells from Sle1b-BAC90 mice
compared with B6 and B6.Sle1b mice (Fig. 7D, right panel).
Phosphoflow analysis of B cells after conjugate formation with
OT-II T cells showed similar phosphorylation levels of BTK and
p38-MAPK among all three strains (Fig. 7E, 7H) but reduced
phosphorylation of Erk and Syk in B cells from B6.Sle1b mice
compared with B6 and Sle1b-BAC90 mice (Fig. 7F, 7G). These
data suggest that differential expression of CD84 and Ly108 on
B cells could alter B and T cell interactions, resulting in reduced
BCR signaling. It is plausible that such variations in the frequency
of B and T cell interactions and lower BCR signaling might allow
autoimmune B cells to escape the GC tolerance checkpoint.
Discussion
Polymorphisms in SLAM family genes are implicated in both
murine and human lupus (1, 2, 17, 25–27). Using B6.Sle1b mice
that express the NZM2410/NZW lupus strain–derived SLAM
family genes, we showed previously that this sublocus alters B cell
tolerance at the GC checkpoint, leading to increased ANA-specific
AFCs and ANA titers (3, 16). However, the mechanisms by which
B cell–intrinsic expression of polymorphic SLAM family genes
may alter B cell tolerance at the GC checkpoint and the SLAM
family members required for mediating this process were not
Table I. List of antiapoptotic genes upregulated in B cells from
B6.Sle1b mice
Gene Name Fold Change p Value
BCL2L1 2.2 0.03
SPHK1 2.2 0.007
HMGB2 2.5 0.048
BIRC5 2.6 0.011
RRM2 1.9 0.018
METAP2 1.6 0.031
These antiapoptotic genes were significantly upregulated in sorted B cells derived
from 3-mo-old B6.Sle1b mice, as determined by Illumina Bead Chip arrays (Mouse
WG-6 V2). Gene expression is shown in terms of increased fold change in B6.Sle1b
mice compared with B6 controls. Statistical analysis was performed using the pair-
wise homogeneous t test.
FIGURE 7. Reduced B cell–T cell conjugate formation in B6.Sle1bmice. (A) Representative flow cytometry plots of B220+ B cell and CD4+ OT-II T cell
conjugate formation (left panel). Conjugate formation was calculated as B220+CD4+ double positive for each mouse group over the course of 60 min. Line
graph of the kinetics of B cell–T cell conjugate formation (right panel). Representative 2D confocal images of B6 B cells (blue) and OT-II T cells (green) in
coculture at 30 min (B) and 50 min (C). The B and T cells in contact with each other are shown in yellow. Scale bars, 20 mm. (D) Average percentage (left
panel) and duration (right panel) of contacts between OT-II T cells and B cells from the indicated strains over a 60-min period. The analysis was performed
twice, with B cells pooled from two or three mice/group. (E–H) Kinetics of phosphorylation of BtK, Erk, p38/MAPK, and Syk in B cells during conjugate
formation with T cells over the course of 30 min. *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001.
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addressed. In this study, by analyzing seven B6.Sle1b mouse lines
carrying various BAC transgenes of B6 alleles of SLAM and non-
SLAM family genes spanning the entire Sle1b locus, we identified
that Ly108 and CD84 play essential roles in the loss of B cell
tolerance in B6.Sle1b mice. Overexpression of B6 wild-type
CD84 and Ly108 can restore B cell tolerance at the GC check-
point, leading to reduced numbers of ANA-specific long-lived
AFCs in BM. Subsequently, taking advantage of GC B cell–spe-
cific Cre mice in which Cre conditionally removed transgenically
expressed B6 alleles of CD84 and Ly108 on GC B cells, we
further demonstrate that the expression of polymorphic CD84 and
Ly108 on GC B cells is critical for the loss of tolerance to nuclear
Ags in B6.Sle1b mice. These results highlight the importance of
CD84 and Ly108 expression on GC B cells in regulating Spt-GC
and Tfh cell responses and in preventing autoimmunity.
Our in vitro functional assays revealed lower Ca2+ flux, reduced
proliferation, and apoptosis of B cells expressing Sle1b compared
with B6, all of which were restored in Sle1b-BAC90 mice over-
expressing B6 alleles of CD84 and Ly108. Consistent with these
data, we found reduced levels of phosphorylation of several mol-
ecules in the BCR signaling pathway in B cells from B6.Sle1b
mice, whereas B6 and Sle1b-BAC90 mice showed comparable
levels of phosphorylation of these molecules. Our results are
consistent with a previous report (4) showing lower Ca2+ flux and
less cell death of hen egg lysozyme (HEL)-transgenic B cells
expressing Sle1b (Sle1b-HEL transgenic) upon BCR stimulation.
However, Kumar et al. (4) reported increased proliferation of
Sle1b-HEL–transgenic B cells, whereas we found a modest re-
duction in the proliferation of B cells expressing Sle1b. This
discrepancy in the proliferation of Sle1b B cells may have resulted
from the difference in Ag specificity (i.e., HEL transgenic versus
polyreactive).
The mechanism by which autoreactive B cells in B6.Sle1b mice
are selected into autoantibody-producing long-lived AFCs or
memory B cells is not clear. Based on our data showing reduced
proliferation and apoptosis of B cells expressing Sle1b and the
reversal of these phenotypes with overexpression of B6-derived
CD84 and Ly108, we suggest that the increased spontaneous GC,
Tfh cell, and long-lived AFC responses in B6.Sle1b mice may not
be the result of an enhanced positive selection of autoreactive
B cells in GCs. Rather, we believe that autoreactive B cell de-
velopment in GCs of B6.Sle1b mice is due to altered negative
selection of GC B cells. We propose two plausible mechanisms by
which polymorphic SLAM expression in B cells from B6.Sle1b
mice may help autoreactive B cells escape negative selection in
GCs. One mechanism is that polymorphic SLAM expression in
B6.Sle1b B cells helps to reduce BCR signaling upon engagement
of self-Ags, which allows these cells to survive in the GC and not
undergo negative selection.
We propose a second scenario whereby GC B cells interact with
T cells. Given the increased frequency of Tfh cells in B6.Sle1b
mice, the chances of B cell–T cell interactions in GCs are very
high. Therefore, given our data from the conjugate assay, we
suggest that reduced B cell–T cell conjugates, resulting from
B cell–intrinsic expression of polymorphic SLAMs, helps to
maintain reduced BCR signaling in B cells expressing Sle1b. On
one hand, this differential frequency of interaction of B6.Sle1b
B cells with T cells may help autoreactive B cells to escape
negative selection in GCs by reducing BCR signaling; on the other
hand, it provides sufficient survival signals to these B cells to
proliferate (albeit at a slower rate than B6 controls) and differ-
entiate into autoantibody-producing AFCs. Consistent with this
idea, we previously observed augmented GC responses of DNA
and p-azophenylarsonate dual-reactive B cells from Ig VH knock-
in mice (named HKIR) expressing Sle1b (16). Under non-
autoimmune conditions, because of their DNA reactivity, HKIR
p-azophenylarsonate–DNA dual-reactive B cells are negatively
regulated in GCs, presumably by the GC tolerance checkpoint
(28–30). However, autoimmune susceptibility, as in B6.Sle1b mice,
alters their negative selection in GCs (16). Recently, Sinai et al. (31)
also reported that altered B and T cell interactions were responsible
for an increased GC B cell phenotype in vitro in autoimmune-prone
B6.Sle1b mice.
Anergic B cells have arrested development, are excluded from
B cell follicles, and are unable to mobilize calcium (32). Anergic
B cells are also unable to proliferate, upregulate activation markers,
mediate BCR signaling, or mount an immune response after BCR
engagement (32). Our results show that B6.Sle1b B cells exhibit
normal B cell development in the BM and spleen, are present in
B cell follicles, and seed GCs; thus, they do not exhibit an anergic
state. Analysis of the cellular energy metabolism also indicates
that reduced calcium mobilization and lower BCR signaling upon
stimulation of B6.Sle1b B cells do not dampen the energy metab-
olism in these cells. B6.Sle1b B cells appear to be comparable, if
not better, in responding to the high-energy demands upon activa-
tion. In a recent comparative analysis, Rathmell and colleagues (33)
found that anergic B cells were metabolically suppressed, whereas
B cells from autoimmune BAFF-transgenic mice were metaboli-
cally more active with increased glycolytic efficiency, which was
necessary for autoantibody production. This study is in line with our
data showing that B6.Sle1b B cells are not anergic; rather, they can
undergo optimal metabolic reprogramming upon activation to pro-
duce high titers of autoantibodies.
The functional and mechanistic roles of Ly108 and CD84 in the
context of GCs are unclear. Ly108 was proposed to act as a mo-
lecular rheostat that determines the stringency with which auto-
reactive B cells are purged during primary development (4),
whereas other studies suggested similar functions for Ly108 in
T cells (5, 34). Although our data indicate that polymorphisms in
CD84 and Ly108 in B cells determine the efficiency of tolerance,
we cannot exclude a possible contribution of Ly108 expression by
T cells, particularly with respect to the production of IFN-g (35).
IFN-g was demonstrated to drive pathogenic accumulation of Tfh
cells in Roquinsan mice and promote Ab class switching to path-
ogenic IgG2c, both of which are observed in B6.Sle1b mice (36–38).
Although CD84 and Ly108 were demonstrated to be integral for
optimal GC responses against protein immunization (23), no such
defect was observed in mice deficient in CD84 in the context of
an acute lymphocytic choriomeningitis virus or vaccinia virus
infection (24). Our analysis also revealed no defect in spontaneous
or SRBC-induced GC and Tfh cell responses in mice deficient in
either CD84 or Ly108 (data not shown). These data indicate re-
dundancy in functions of SLAM family receptors; however, these
earlier studies did not investigate the B cell–intrinsic expression of
polymorphic CD84 and Ly108 in the Spt-GC response. Our data
suggest that CD84 and Ly108 function in a regulatory capacity in
B cells, because Spt-GC responses correlated inversely with CD84
and Ly108 expression, specifically on GC B cells (data not shown).
In addition, in vitro stimulation with anti-Ly108 resulted in in-
creased CD84 levels on activated B6 B cells, which was defective
in Sle1b B cells but mostly restored in Sle1b-BAC90 B cells (data
not shown), indicating that the functions of these two SLAM family
genes may be tightly linked. These data suggest that altered sig-
naling in B cells mediated by Sle1b-derived CD84 and Ly108 may
lead to a modulation in B and T cell interactions and subsequent
selection in GCs. Consistent with this idea, we observed impaired B
and T cell conjugation when B cells expressed Sle1b, which was
restored by B cell expression of wild-type CD84 and Ly108.
The Journal of Immunology 4141
 at D
e D
uve Institute on A
pril 21, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
Earlier studies focused on SLAM signaling in T cells and NKT
cells owing to the discovery of the SAP molecule, which is highly
expressed in these cell types (2). SAP regulates T cell–mediated
help (39), Tfh cell development (40), cytokine production (41), and
GC response (42). SAP expression in T cells, but not in B cells, is
required for a humoral immune response (43). Ly108 also was
shown to regulate T cell signaling via the SAP–Fyn pathway (34).
Crotty and colleagues (24) further suggested that Ly108 regulates
T cell and B cell interactions by modulating the ratio of positive/
negative signals mediated by SAP and SHP-1. The requirement
for SAP and T cells in autoimmune responses also was described
in lupus-prone MRL-FASlpr (44), Sanroque (45), and B6.Sle1b
mice (46).
Although previous studies highlighted the importance of SLAM–
SAP signaling within T cells in shaping T cell–mediated B cell
responses, whether similar signaling mechanism exists in B cells
has not been defined previously. Detre et al. (47) recently reported
the role of SAP in modulating B cell functions. Because B cells do
not express SAP, the mechanism by which SAP deficiency alters
the B cell response is not clear. We observed no differences in SAP
transcript levels in T and B cells (including Tfh cells and GC
B cells) among B6, B6.Sle1b, and Sle1b-BAC90 mice. A recent
study implicated the role of SAP-related molecule EAT-2 in me-
diating its effects in NK cells by linking SLAM family receptors to
phospholipase Cg, calcium flux, and Erk kinase (48). Whether
signaling through this or other unknown adaptor molecules is
compromised in B6.Sle1b B cells, resulting in lower calcium flux
and reduced Erk phosphorylation, remains to be determined.
In summary, we showed that CD84 and Ly108 expression on GC
B cells is critical for maintaining peripheral B cell tolerance at
the GC checkpoint. Our data further highlight the importance of the
GC pathway in autoimmune disease pathogenesis and suggest that
GC B cell–specific CD84 and Ly108 may be therapeutic targets
for systemic lupus erythematosus.
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